[HTML][HTML] Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo …
MG Johnson, JM Strizki, ML Brown, H Wan… - Infection, 2023 - Springer
Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled …
MG Johnson, JM Strizki, ML Brown, H Wan… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
[PDF][PDF] Molnupiravir for the treatment of COVID‑19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo …
MG Johnson, JM Strizki, ML Brown, H Wan… - scienceopen.com
Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled …
MG Johnson, JM Strizki, ML Brown, H Wan… - 2023 - cabidigitallibrary.org
Purpose: Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
[HTML][HTML] Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo …
MG Johnson, JM Strizki, ML Brown, H Wan… - Infection, 2023 - ncbi.nlm.nih.gov
Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled …
MG Johnson, JM Strizki, ML Brown, H Wan… - …, 2023 - experts.nebraska.edu
Purpose: Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled …
MG Johnson, JM Strizki, ML Brown, H Wan… - …, 2023 - search.ebscohost.com
Purpose: Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …